StreetAlpha.app
Home › Stocks › ACET

Adicet Bio, Inc. (ACET)

$2.14
▼ −13.01%
LAST CLOSE · NOV 20

Adicet Bio develops gamma delta T cell therapies made from donor cells for autoimmune diseases and cancer. It last closed at $2.14 on Nov 20, down 13.01% on the day. The next earnings report for ACET is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, ACET reported EPS of -$1.76. Over its last 8 reports the stock moved an average of 7.6% the session after earnings. Over the last 12 months ACET insiders bought $1.6M of stock on the open market and sold $675K, according to SEC Form 4 filings.

AI Auto Pilots
Is ACET in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ACET.

Key Stats

Last 12 months
Results
Net income
−$91.0M
EPS (diluted)
−$7.47
Free cash flow
−$80.4M
Valuation
Market cap
$20.0M
9.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$27.1M
At Sep 30
Shareholder equity
$102.7M
Shares outstanding
9.4M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$62.0M−$62.0MFY2021FY2022: −$69.8M−$69.8MFY2022FY2023: −$142.7M−$142.7MFY2023FY2024: −$117.1M−$117.1MFY2024FY2025: −$116.8M−$116.8MFY2025

From ACET's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 11
Estimated date · After the close
Reported EPS
-$1.76
Quarter ended Sep 2026
Year ago EPS
-$4.72
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$20.31Dec '24Mar 2025: -$4.96Mar '25Jun 2025: -$5.48Jun '25Sep 2025: -$4.72Sep '25Dec 2025: -$1.85Dec '25Mar 2026: -$1.88Mar '26Jun 2026: -$1.99Jun '26Sep 2026: -$1.76Sep '26Latest -$1.76
Revenue by quarter
Not enough quarters on file yet.
How ACET moved after its last 8 reports
Average move the session after a report ±7.6%
Nov 5, 2026After the close+4.5%
Aug 5, 2026After the close−13.4%
May 13, 2026After the close+4.2%
Mar 12, 2026After the close+2.4%
Nov 5, 2025After the close−1.9%
Aug 7, 2025After the close−9.6%
May 6, 2025After the close−18.6%
Mar 6, 2025After the close−5.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ACETStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ACET
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ACET

Technical Analysis

ACET · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 43% below its 20 day and 144% below its 50 day average. It is 241% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 13), oversold. The nearest support is the 52 week low at $2.12, and the nearest resistance the Pivot at $2.26.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 15.3%/day
Key levels
$11.1552 week high+421.0%
$8.37Swing high (Jun 15)+291.1%
$7.30200 day average+241.1%
$7.01100 day average+227.6%
$5.2350 day average+144.4%
$3.0720 day average+43.5%
$2.41Pivot R1+12.6%
$2.26Pivot+5.6%
$2.14Last close
$2.1252 week low−0.9%
$2.00Pivot S1−6.5%
Indicators
RSI (14)13.39Oversold below 30Oversold
MACD-0.76Above its signal lineBullish
Stochastic4.9Near the bottom of its rangeOversold
ADX (14)69.0Strong downtrend
Williams %R-98.4Oversold below −80, overbought above −20Oversold
CCI (20)-155.8Oversold below −100, overbought above 100Oversold
Rate of change−29.8%Change over 10 sessionsBearish
ATR (14)$0.33Typical daily range, 15.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ACET

What happened before

See how ACET did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ACET usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ACET has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ACETHow many large options trades hit ACET, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ACET Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼20 buying vs 24 selling
  • ▼Held by funds -3.7 pts
  • ▼Funds holding -2
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding5456−3.6%
In funds' top 10220.0%
Held by funds61.5%65.3%−3.7 pts
New / increased5 / 1514 / 18−37.5%
Reduced / sold out17 / 79 / 7+50.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACET institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ACET Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$1.6M1 buy · 1 insider
Sold$675K1 sale · 1 insider
2026-02 bought $1.6M2026-04 sold $675KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Apr 8Orbimed Advisors LLC10% ownerSale104,658$6.45$675K
Feb 20Ra Capital Management, L.P.10% ownerBuy223,596$7.17$1.6M
Oct 8, 2025Orbimed Advisors LLC10% ownerBuy5,000,000$1.00$5.0M
Every insider buy and sale for ACET over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ACET insider trades →

From SEC Form 4 filings by ACET's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACET is in one of them and how their past ACET trades turned out.

ACET in the AI portfolios
Loading…

ACET News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACET in an article yet. Here's the latest on the wider market.

ACET in the news

About Adicet Bio

Adicet Bio is a biotechnology company based in Boston, Massachusetts. It develops allogeneic gamma delta T cell therapies, made from donor cells so that they can be stored and given to patients on demand. Its lead candidate is being tested for autoimmune diseases such as lupus, and it is also developing a candidate for prostate cancer. The company's therapies are intended for patients with autoimmune diseases and cancer, and they are still in clinical trials.

Headquarters
Boston, MA